Mundipharma Malaysia – Hans Kim, Country Manager
Mundipharma Malaysia’s country manager discusses his company’s aim to become a reference in Malaysia for pain management, on the back of the tremendous 48 percent growth of the business last year. …
We do things differently at Mundipharma International. Our approach is nothing like the traditional pharmaceutical business model. Innovation guides everything we do and our success rate proves our approach works.
We make it our business to watch, respond and adapt to new market pressures. We are a boutique organisation that is built on an entrepreneurial spirit – we are always looking for the right opportunity. This flexible approach means that very few doors are closed to us: we see an opportunity, we get the right people in and we go for it.
We develop partnerships with a wide range of pharmaceutical and biotech companies around Europe and the rest of the world.
We provide fully integrated, strategic support and services to individual companies within the Mundipharma network.
And we help our partners gain approval from regulators and build markets for their products.
Mundipharma Malaysia’s country manager discusses his company’s aim to become a reference in Malaysia for pain management, on the back of the tremendous 48 percent growth of the business last year. …
Clinical Research Malaysia’s CEO discusses the need for Malaysia to focus on high quality pivotal trials rather than simply on a high number of trials. He shares with us the…
The National Heart Institute’s CEO portrays IJN as a national referral center for cardiovascular disease and declares: “IJN is equipped with the best in class technologies and is poised to…
“We believe the future lies with Universal health coverage and the formulation of one and only healthcare, with the merger of public and private sector under one reimbursement system” says…
PEMANDU’s Director for the Healthcare National Key Economic Area gives a thorough understanding of the various entry point projects that were implemented since 2010 to help Malaysia become a high…
Stefan Oschmann, President of the Emerging Markets at Merck and Co. described MSD as the dark horse of the emerging markets. How is MSD performing in Malaysia? Since the merger…
PhAMA was started in 1972 and now has most of the MNC players among its members which include 43 companies. How has the association evolved since its origin and what…
The pharmaceutical industry has been targeted as one of the key growth sectors for the Malaysian economy under the 10th Malaysia Plan, how successful in your opinion have the government…
Without a doubt, Malaysia shares all the major attributes of an emerging market, from the potential to expand market penetration to the increasing purchasing power of the population. So…
2011 marks the 10th anniversary of the company. Over that time you’ve enjoyed notable success including being the first Asian CRO to attain OECD GLP accreditation. Talk us through your…
Since its origin, Emerging Pharma has been helping foreign pharma companies to enter Malaysia. However, the Malaysian market is relatively small. Why should international pharma companies look to this country…
How would you describe the operating environment for foreign companies to use the services of Malaysian companies and how can you reassure these multinationals that sufficient intellectual property protection is…
Malaysia has good ethnic diversity, cost-effective infrastructure, and highly qualified principal investigators (PIs) and these elements have been in place for a long time. Why is now is the right…
See our Cookie Privacy Policy Here
